Liquidia(NASDAQ) LQDA

Liquidia Corporation makes medicines to help people breathe better. It creates treatments for serious heart and lung diseases. The company aims to make daily care easier for patients.

Helping People Breathe Easier

• YUTREPIA: Inhaled dry powder for treating high blood pressure in the lungs; began commercialization in June 2025.
• Treprostinil Injection: Generic injectable medication sold through a promotion agreement with Sandoz.
• PRINT Technology: Engineering platform used to create uniform drug particles for delivery into the deep lung.

What's Next for the Pipeline?

• Launched YUTREPIA in June 2025 after receiving full approval from the Food and Drug Administration.
• Licensed L606 from Pharmosa Biopharm to develop a twice-daily inhaled treatment for lung conditions.
• Expanded the L606 license in 2026 to include markets in Europe and Japan.
• Achieved a $1.0 million development milestone under a device license agreement with Vectura.

Precision Particle Engineering

Liquidia uses its owned PRINT technology to manufacture drug particles with specific sizes to improve how they work in the body. The company employs a specialized sales force that works directly with healthcare providers who treat rare lung diseases.

Revenue Growth and Profitability

• Net product sales reached $170.4 million in the three-month period ended June 30, 2026, up 2,514.4% year over year.
• Net income was $74.7 million for the three-month period ended June 30, 2026, up 280% year over year.
• Cash and cash equivalents totaled $284.2 million as of June 30, 2026.
• Research and development expenses were $17.2 million in the quarter ended June 30, 2026, up 185% year over year.

Moving Toward Commercial Success

Liquidia has transitioned from a research firm to a commercial company with the launch of its inhaled treprostinil product. Its focus on specialized delivery technology and new treatment indications supports its growth in the respiratory health market.